What is the current valuation of the oral anticoagulants market in South Korea as of 2024?

The oral anticoagulants market in South Korea was valued at $619.0 Million in 2024. Read More

What is the projected market valuation for oral anticoagulants in South Korea by 2035?

The market is projected to reach $1197.0 Million by 2035. Read More

What is the expected CAGR for the South Korea oral anticoagulants market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 6.18%. Read More

Which product segment had the highest valuation in 2024 within the South Korea oral anticoagulants market?

In 2024, the Novel Oral Anticoagulants segment had a valuation of $370.0 Million. Read More

How did the Warfarin segment perform in terms of valuation in 2024?

The Warfarin segment was valued at $249.0 Million in 2024. Read More

What disease indication segment generated the highest revenue in 2024 for oral anticoagulants?

The Atrial Fibrillation segment generated the highest revenue, valued at $248.0 Million in 2024. Read More

What are the projected revenues for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) segments by 2035?

Both the DVT and PE segments are projected to reach $240.0 Million by 2035. Read More

Which distribution channel is expected to show significant growth in the South Korea oral anticoagulants market?

The Retail Pharmacies channel, valued at $250.0 Million in 2024, is expected to show significant growth. Read More

Who are the key players in the South Korea oral anticoagulants market?

Key players include Bristol-Myers Squibb, Bayer, Johnson & Johnson, Sanofi, Pfizer, AstraZeneca, Daiichi Sankyo, Roche, and Merck & Co. Read More

What is the expected market trend for the oral anticoagulants market in South Korea over the next decade?

The market is expected to experience steady growth, driven by an anticipated CAGR of 6.18% from 2025 - 2035. Read More

South Korea Oral Anticoagulants Market

South Korea Oral Anticoagulants Market Research Report By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Disease Indication (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Heart Attacks) and By Product (Novel Oral Anticoagulant, Warfarin) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.18%

2024 Market Size

$ 619 Million

2035 Market Size

$ 1,197 Million

Healthcare ● Updated February 2026 Report ID: MRFR/HC/51462-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Product (USD Million)
  1. 4.1.1 Novel Oral Anticoagulants
  2. 4.1.2 Warfarin
2. 4.2 Security, Access Control and Robotics, BY Disease Indication (USD Million)
  1. 4.2.1 Atrial Fibrillation
  2. 4.2.2 Deep Vein Thrombosis (DVT)
  3. 4.2.3 Pulmonary Embolism (PE)
  4. 4.2.4 Heart Attacks
3. 4.3 Security, Access Control and Robotics, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Daiichi Sankyo (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY PRODUCT
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
8. 6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 (% SHARE)
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 TO 2035 (USD Million)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISEASE INDICATION, 2024 (% SHARE)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea South Korea Oral Anticoagulants Market Segmentation

South Korea Oral Anticoagulants Market By Product (USD Million, 2025-2035)

Novel Oral Anticoagulants
Warfarin

South Korea Oral Anticoagulants Market By Disease Indication (USD Million, 2025-2035)

Atrial Fibrillation
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Heart Attacks

South Korea Oral Anticoagulants Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”